Skip to main content
Top
Published in: International Urology and Nephrology 4/2011

01-12-2011 | Nephrology – Original Paper

Significance of serum and urine neuraminidase activity and serum and urine level of sialic acid in diabetic nephropathy

Authors: Jamshid Roozbeh, Ahmad Merat, Farahnaz Bodagkhan, Raha Afshariani, Hooman Yarmohammadi

Published in: International Urology and Nephrology | Issue 4/2011

Login to get access

Abstract

Background

Prospective studies have reported associations among various markers of inflammation and the incidence of diabetes, and it has been proposed that inflammation has a causal role in the development of diabetes. The objective of this study was to investigate the significance of serum and urine neuraminidase activity (NA) and serum and urine sialic acid (SA) level in patients with Diabetic nephropathy.

Methods

In a prospective study, 190 diabetic patients with established diabetic nephropathy, 30 type 2 diabetes patients without any diabetic related nephropathy, and 36 non-diabetic patients with diagnosed nephropathy were enrolled. Two hundred and forty healthy individuals without diabetes or kidney disease were also enrolled as control group. Fasting venous blood samples and urine samples were collected and checked for serum and urine NA and SA level.

Results

In the diabetic nephropathy group, the mean value of serum and urine NA was 64.6 ± 2.6 and 11.7 ± 1.2 mU/ml, respectively, and mean values of serum and urine SA were 93.2 ± 3.6 and 17.7 ± 1.4 mg/dl, respectively. Serum and urine NA and SA levels were significantly higher in patient with diabetic nephropathy when compared to the other groups (P < 0.001).

Conclusions

Our study suggests that there is a strong association between elevated serum and urine NA and serum and urine SA levels with the presence of diabetic nephropathy in type 2 diabetic patients. Further investigations are needed on the diagnostic and prognostic significance of these two inflammatory markers.
Literature
1.
go back to reference Nayak BS, Roberts L (2006) Relationship between inflammatory markers, metabolic and anthropometric variables in the Caribbean type 2 diabetic patients with and without microvascular complications. J Inflamm (Lond) 22(3):17CrossRef Nayak BS, Roberts L (2006) Relationship between inflammatory markers, metabolic and anthropometric variables in the Caribbean type 2 diabetic patients with and without microvascular complications. J Inflamm (Lond) 22(3):17CrossRef
2.
go back to reference Berns G, O’Kennedy R (1990) A study of N-acetylneuraminic acid in relation to its potential as a marker of tumour development. Biochem Soc Trans 18(2):333–334PubMed Berns G, O’Kennedy R (1990) A study of N-acetylneuraminic acid in relation to its potential as a marker of tumour development. Biochem Soc Trans 18(2):333–334PubMed
3.
go back to reference Taniuchi K, Chifu K, Hayashi N, Nakamachi Y, Yamaguchi N, Miyamoto Y, Doi K, Baba S, Uchida Y, Tsukada Y, Sugimori T (1981) A new enzymatic method for the determination of sialic acid in serum and its application for a marker of acute phase reactants. Kobe J Med Sci 27(3):91–102PubMed Taniuchi K, Chifu K, Hayashi N, Nakamachi Y, Yamaguchi N, Miyamoto Y, Doi K, Baba S, Uchida Y, Tsukada Y, Sugimori T (1981) A new enzymatic method for the determination of sialic acid in serum and its application for a marker of acute phase reactants. Kobe J Med Sci 27(3):91–102PubMed
4.
go back to reference Yokoyama H, Jensen JS, Jensen T, Deckert T (1995) Serum sialic acid concentration is elevated in IDDM especially in early diabetic nephropathy. J Intern Med 237(5):519–523PubMedCrossRef Yokoyama H, Jensen JS, Jensen T, Deckert T (1995) Serum sialic acid concentration is elevated in IDDM especially in early diabetic nephropathy. J Intern Med 237(5):519–523PubMedCrossRef
5.
go back to reference Seppala R, Renlund M, Bernardini I, Tietze F, Gahl WA (1990) Renal handling of free sialic acid in normal humans and patients with Salla disease or renal disease. Lab Invest 63(2):197–203PubMed Seppala R, Renlund M, Bernardini I, Tietze F, Gahl WA (1990) Renal handling of free sialic acid in normal humans and patients with Salla disease or renal disease. Lab Invest 63(2):197–203PubMed
6.
go back to reference Ozben T (1991) Elevated serum and urine sialic acid levels in renal diseases. Ann Clin Biochem 28(Pt 1):44–48PubMed Ozben T (1991) Elevated serum and urine sialic acid levels in renal diseases. Ann Clin Biochem 28(Pt 1):44–48PubMed
7.
go back to reference Tomino Y, Inoue W, Yagame M, Nomoto Y, Sakai H, Ito K, Nagaoka K, Ikeda N (1988) Measurement of sialic acid and acute phase reactant proteins in sera of patients with diabetic nephropathy. J Diabet Complications 2(4):175–178PubMedCrossRef Tomino Y, Inoue W, Yagame M, Nomoto Y, Sakai H, Ito K, Nagaoka K, Ikeda N (1988) Measurement of sialic acid and acute phase reactant proteins in sera of patients with diabetic nephropathy. J Diabet Complications 2(4):175–178PubMedCrossRef
8.
go back to reference Bhide S, Parekh AJ, Desai MP (1998) Sialic acid levels in serum and CSF in infections and non-infections conditions. Biochem Med 18:99–101CrossRef Bhide S, Parekh AJ, Desai MP (1998) Sialic acid levels in serum and CSF in infections and non-infections conditions. Biochem Med 18:99–101CrossRef
9.
go back to reference Shamberger RJ (1984) Serum sialic acid in normals and in cancer patients. J Clin Chem Clin Biochem 22(10):647–651PubMed Shamberger RJ (1984) Serum sialic acid in normals and in cancer patients. J Clin Chem Clin Biochem 22(10):647–651PubMed
10.
go back to reference Van Pelt J, Van Bilsen DG, Kamerling JP, Vliegenthart JF (1988) Structural analysis of O-glycosidic type of sialyloligosaccharide-alditols derived from urinary glycopeptides of a sialidosis patient. Eur J Biochem 174(1):183–187PubMedCrossRef Van Pelt J, Van Bilsen DG, Kamerling JP, Vliegenthart JF (1988) Structural analysis of O-glycosidic type of sialyloligosaccharide-alditols derived from urinary glycopeptides of a sialidosis patient. Eur J Biochem 174(1):183–187PubMedCrossRef
11.
go back to reference Lindberg G, Iso H, Råstam L, Lundblad A, Folsom AR (1997) Serum sialic acid and its correlates in community samples from Akita, Japan and Minneapolis, USA. Int J Epidemiol 26(1):58–63PubMedCrossRef Lindberg G, Iso H, Råstam L, Lundblad A, Folsom AR (1997) Serum sialic acid and its correlates in community samples from Akita, Japan and Minneapolis, USA. Int J Epidemiol 26(1):58–63PubMedCrossRef
12.
go back to reference Doğan H, Paşaoğlu H, Ekinciler OF, Tatlişen N (1992) A comparative study of total protein, total and lipid associated serum sialic acid levels in patients with Behçet’s disease and control groups. Acta Ophthalmol (Copenh) 70(6):790–794 Doğan H, Paşaoğlu H, Ekinciler OF, Tatlişen N (1992) A comparative study of total protein, total and lipid associated serum sialic acid levels in patients with Behçet’s disease and control groups. Acta Ophthalmol (Copenh) 70(6):790–794
13.
go back to reference Sillanaukee P, Pönniö M, Jääskeläinen IP (1999) Occurrence of sialic acids in healthy humans and different disorders. Eur J Clin Invest 29(5):413–425PubMedCrossRef Sillanaukee P, Pönniö M, Jääskeläinen IP (1999) Occurrence of sialic acids in healthy humans and different disorders. Eur J Clin Invest 29(5):413–425PubMedCrossRef
14.
go back to reference Rellier N, Ruggiero-Lopez D, Lecomte M, Lagarde M, Wiernsperger N (1999) In vitro and in vivo alterations of enzymatic glycosylation in diabetes. Life Sci 64(17):1571–1583PubMedCrossRef Rellier N, Ruggiero-Lopez D, Lecomte M, Lagarde M, Wiernsperger N (1999) In vitro and in vivo alterations of enzymatic glycosylation in diabetes. Life Sci 64(17):1571–1583PubMedCrossRef
15.
go back to reference Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356–360PubMedCrossRef Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356–360PubMedCrossRef
16.
go back to reference Denny PC, Denny PA, Allerton SE (1983) Determination of sialic acid using 2-thiobarbituric acid in the absence of hazardous sodium arsenite. Clin Chim Acta 131(3):333–336PubMedCrossRef Denny PC, Denny PA, Allerton SE (1983) Determination of sialic acid using 2-thiobarbituric acid in the absence of hazardous sodium arsenite. Clin Chim Acta 131(3):333–336PubMedCrossRef
17.
go back to reference Ziegler D, Hutchinson H (1972) Coupled enzyme system for measuring viral neuraminidase activity. Appl Microb 23:1060 Ziegler D, Hutchinson H (1972) Coupled enzyme system for measuring viral neuraminidase activity. Appl Microb 23:1060
18.
go back to reference Parkkinen J, Finne J (1983) Isolation and structural characterization of five major sialyloligosaccharides and a sialylglycopeptide from normal human urine. Eur J Biochem 136(2):355–361PubMedCrossRef Parkkinen J, Finne J (1983) Isolation and structural characterization of five major sialyloligosaccharides and a sialylglycopeptide from normal human urine. Eur J Biochem 136(2):355–361PubMedCrossRef
19.
go back to reference Carter A, Martin NH (1962) Serum Sialic acid levels in health and disease. J Clin Pathol 15:69–72PubMedCrossRef Carter A, Martin NH (1962) Serum Sialic acid levels in health and disease. J Clin Pathol 15:69–72PubMedCrossRef
20.
go back to reference Sonnez H, Ozturk ZG, Ulutin T, Domanc N, Kokoglu E (2000) Carbohydrate deficient transferring and sialidase level in coronary heart disease. Throm Res 99:311–315CrossRef Sonnez H, Ozturk ZG, Ulutin T, Domanc N, Kokoglu E (2000) Carbohydrate deficient transferring and sialidase level in coronary heart disease. Throm Res 99:311–315CrossRef
21.
go back to reference Crook MA, Couchman S, Tutt P (1996) Plasma fibrinogen and its relationship to plasma sialic acid in non-insulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis 7(6):586–589PubMedCrossRef Crook MA, Couchman S, Tutt P (1996) Plasma fibrinogen and its relationship to plasma sialic acid in non-insulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis 7(6):586–589PubMedCrossRef
22.
go back to reference Izumida Y, Seiyama A, Maeda N (1991) Erythrocyte aggregation: bridging by macromolecules and electrostatic repulsion by sialic acid. Biochem Biophys Acta 1067(2):221–226PubMedCrossRef Izumida Y, Seiyama A, Maeda N (1991) Erythrocyte aggregation: bridging by macromolecules and electrostatic repulsion by sialic acid. Biochem Biophys Acta 1067(2):221–226PubMedCrossRef
23.
go back to reference Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in β-cells of the rat pancreas. Physiol Res 50(6):537–546PubMed Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in β-cells of the rat pancreas. Physiol Res 50(6):537–546PubMed
24.
go back to reference Ozen T, Nacitarhan S, Tuncer N (1995) Plasma and urine sialic acid in non-insulin dependent diabetes mellitus. Ann Clin Biochem 32(Pt 3):303–306 Ozen T, Nacitarhan S, Tuncer N (1995) Plasma and urine sialic acid in non-insulin dependent diabetes mellitus. Ann Clin Biochem 32(Pt 3):303–306
25.
go back to reference Asami T, Tanaka A, Gunji T, Sakai K (1985) Elevated serum and urine sialic acid levels in renal disease of childhood. Clin Nephrol 23(3):112–119PubMed Asami T, Tanaka A, Gunji T, Sakai K (1985) Elevated serum and urine sialic acid levels in renal disease of childhood. Clin Nephrol 23(3):112–119PubMed
26.
go back to reference Ponnio M, Altho H, Nikkari ST, Olsson U, Rydberg U, Sillanaukee P (1999) Serum sialic acid in a random sample of the general population. Clin Chem 45(10):1842–1849PubMed Ponnio M, Altho H, Nikkari ST, Olsson U, Rydberg U, Sillanaukee P (1999) Serum sialic acid in a random sample of the general population. Clin Chem 45(10):1842–1849PubMed
27.
go back to reference Crook M, Collins D, Lumb P, Fogelman I, Treloar A (1998) The relationship between the female menopause and serum sialic acid, a known cardiovascular risk factor. Eur J Obstet and Gynecol Reprod Biol 76(2):185–187CrossRef Crook M, Collins D, Lumb P, Fogelman I, Treloar A (1998) The relationship between the female menopause and serum sialic acid, a known cardiovascular risk factor. Eur J Obstet and Gynecol Reprod Biol 76(2):185–187CrossRef
28.
go back to reference Pickup JC, Mattock MB, Crook MA, Chusney GD, Burt D, Fitzgerald AP (1995) Serum sialic acid concentration and coronary heart disease in NIDDM. 1995. Diabetes Care 18(8):1100–1103PubMedCrossRef Pickup JC, Mattock MB, Crook MA, Chusney GD, Burt D, Fitzgerald AP (1995) Serum sialic acid concentration and coronary heart disease in NIDDM. 1995. Diabetes Care 18(8):1100–1103PubMedCrossRef
29.
go back to reference Giordano M, Ciarambino T, Gesuè L, Castellino P, De Simone M, Rinaldi G, D’Amora M, Zito G, Paolisso G, Coppola L (2009) The ratio between kidney volume and function increases with the progression of nephropathy in Type 2 diabetes. Clin Nephrol 72(4):247–251PubMed Giordano M, Ciarambino T, Gesuè L, Castellino P, De Simone M, Rinaldi G, D’Amora M, Zito G, Paolisso G, Coppola L (2009) The ratio between kidney volume and function increases with the progression of nephropathy in Type 2 diabetes. Clin Nephrol 72(4):247–251PubMed
Metadata
Title
Significance of serum and urine neuraminidase activity and serum and urine level of sialic acid in diabetic nephropathy
Authors
Jamshid Roozbeh
Ahmad Merat
Farahnaz Bodagkhan
Raha Afshariani
Hooman Yarmohammadi
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2011
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-010-9891-8

Other articles of this Issue 4/2011

International Urology and Nephrology 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.